<DOC>
	<DOCNO>NCT02640157</DOCNO>
	<brief_summary>The purpose study compare safety efficacy ABT-493/ABT-530 combination Sofosbuvir ( SOF ) Daclatasvir ( DCV ) adult genotype 3 chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety ABT-493/ABT-530 Sofosbuvir Dosed With Daclatasvir Adults With HCV Genotype 3 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Screening laboratory result indicate HCV GT3 infection Chronic HCV infection Subject must treatmentna√Øve Subjects must noncirrhotic History severe , lifethreatening significant sensitivity excipients study drug . Female pregnant , plan become pregnant study , breastfeed ; male whose partner pregnant planning become pregnant study . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . HCV genotype perform screen indicate coinfection one HCV genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>interferon free</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>daclatasvir</keyword>
	<keyword>Sovaldi</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 3</keyword>
	<keyword>Hep C</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Daklinza</keyword>
</DOC>